Global EditionASIA 中文雙語Fran?ais
    Business
    Home / Business / Industries

    HPV vaccine makers eye growth overseas

    Companies make notable inroads abroad amid near market saturation in domestic sector

    By LI JIAYING and LIU ZHIHUA | China Daily | Updated: 2024-11-28 10:19
    Share
    Share - WeChat
    A view of bivalent HPV vaccine of Wantai Biopharm in Chongqing on Nov 8. SUN KAIFANG/FOR CHINA DAILY

    In August, Shandong province's online procurement platform revealed that Walvax's bivalent HPV vaccine was priced at just 27.5 yuan per dose — about the same price as a cup of coffee.

    "Eyeing a higher public health level, a lot of local governments have beefed up efforts to provide free bivalent HPV vaccines for females under 15 through government procurement. And reasonable price reductions happening in this progress are a good thing, as they enhance vaccine accessibility, accelerate domestic substitution and promote a higher vaccination rate, benefiting the industry's healthy development," said Tao Ran, CEO of Beijing Health Guard Biotechnology Inc, an innovative vaccine producer.

    According to the National Health Commission, as of mid-October, the free HPV vaccination policy had covered about 40 percent of women of eligible age nationwide.

    Tao suggested that as competition intensifies in the lower-valent vaccine market, breakthroughs may lie in the higher-valent vaccine segment and the development of vaccines for male indications.

    Health Guard's nine-valent HPV vaccine, covering both male and female indicators, is currently in phase-III clinical trials. Nine-valent products of other players, such as Jiangsu Recbio Technology Co Ltd and Shanghai-based Bovax Biotechnology, are also in advanced clinical stages. Notably, Wantai's application for market entry of its nine-valent HPV vaccine was accepted in August, marking the first such domestic application.

    "Lower and higher-valent vaccines may complement each other in meeting different market needs," Tao said, adding that the former, being cost-effective, meet basic prevention needs, while the latter provide more comprehensive protection and may be chosen by more and more consumers as life quality has been largely improved during recent years.

    Tao also said with the sequential approval of domestic nine-valent vaccines, competition is expected to gradually extend from the female market to the male market and eventually boost overall immunization levels worldwide.

    "China's HPV market still holds tremendous potential. To date, only five HPV vaccines for females have been approved in the country, without anything of the same category for males," he said.

    Data from consultancy Frost & Sullivan showed that in 2020, the number of males in China eligible for HPV vaccination (aged 9 to 45) reached 344 million, requiring about 980 million doses for full vaccination coverage. To date, there are merely three HPV vaccines designed for male use that have entered phase-III clinical trials in China.

    "Many women are already well-informed about cervical cancer and HPV vaccines. With the expansion of indicators to include males in the future, more people are expected to gain awareness of this topic, which will further aid in educating the public about cervical cancer prevention and eradication efforts," said Sun Xiaodong, deputy director of the Shanghai Municipal Center for Disease Control and Prevention.

    For many Chinese vaccine manufacturers, tapping the expanding overseas markets has also become a key step to counter fierce domestic competition and achieve broader growth.

    For example, Health Guard said it is conducting phase-III trials for its nine-valent HPV vaccine in Indonesia and plans to submit a market application to relevant departments by 2025. The company also seeks broader market expansion in other ASEAN countries, it said.

    Wantai's bivalent HPV vaccine has also gained market access in 18 countries, primarily in Asia and Africa, with registration applications underway in 10 additional countries across Asia, Africa and Latin America, the company said.

    In addition, Recbio announced earlier this year a comprehensive strategic partnership with Saudi pharmaceutical company Spimaco, authorizing it to develop, register, and commercialize a nine-valent HPV vaccine in 15 countries in the Middle East and North Africa.

    "There is still significant demand in many developing countries, offering new opportunities for Chinese manufacturers," said Yang Huaiyu, a consumer industry analyst.

    "Southeast Asia, with its large population and low vaccination coverage, presents a promising direction for exports and a vast potential market," said Liu Lihe, executive director at China Insights Consultancy.

    However, the diverse income levels and healthcare systems in Southeast Asian countries mean Chinese manufacturers must adopt tailored sales and consumer education strategies, while also engaging extensively with local public health systems, Liu said.

    |<< Previous 1 2   
    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    CLOSE
     
    国产自无码视频在线观看| 精品多人p群无码| 无码免费一区二区三区免费播放| 亚洲中文字幕久久精品无码APP| 无码专区永久免费AV网站| 日本乱偷人妻中文字幕在线| 亚洲AV中文无码乱人伦| 精品久久久久久久无码| 一本加勒比hezyo无码专区| √天堂中文www官网在线| 日韩乱码人妻无码中文字幕视频| 最新中文字幕AV无码不卡| 欧美日韩中文字幕久久久不卡| 中文字幕精品无码久久久久久3D日动漫| 未满小14洗澡无码视频网站| 国产成人综合日韩精品无码不卡| 久久精品中文字幕一区| 亚洲中文字幕在线乱码| 亚洲欧美日韩中文播放| 日韩精品无码免费视频| 日韩少妇无码一区二区三区 | 日韩中文字幕视频| 中文字幕丰满伦子无码| 大地资源中文在线观看免费版| 国产亚洲情侣一区二区无码AV| 国产精品无码一区二区三级| 久久精品无码专区免费东京热| 亚洲av无码潮喷在线观看 | 久久av无码专区亚洲av桃花岛| 日韩午夜福利无码专区a| 无码中文字幕日韩专区视频| 亚洲AV无码久久精品蜜桃| 无码人妻精品一区二区三区在线 | 中文字幕精品无码一区二区三区| 中文字幕人妻在线视频不卡乱码| 中文字幕av日韩精品一区二区| 伊人蕉久中文字幕无码专区| 中文字幕永久一区二区三区在线观看| 亚洲日本va午夜中文字幕久久| 精品久久久无码人妻中文字幕| 国产色爽免费无码视频|